Unibest

Pharmaceutical intermediates

Regorafenib Intermediates

1 pharmaceutical intermediate for Regorafenib. Indication: Gastrointestinal stromal tumor; Hepatocellular carcinoma; Colorectal cancer.

Submit a ProjectAll intermediates

About Regorafenib

Originator
Bayer Healthcare Pharmaceuticals Inc
Indication
Gastrointestinal stromal tumor; Hepatocellular carcinoma; Colorectal cancer
Approved Date
09/27/2012
DS/DP
06/02/2030

Available intermediates

1 intermediate currently listed for Regorafenib. Request specifications, documentation or a quotation for any item below.

Regorafenib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Amino-3-fluorophenol399-95-1//

Other programs under R

Ramelteon RelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenibRibociclib Succinate

Building toward Regorafenib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →